首页 文献索引 SCI期刊 AI助手
期刊目录筛选

期刊名:Esmo open

缩写:

ISSN:N/A

e-ISSN:2059-7029

IF/分区:8.3/Q1

文章目录 更多期刊信息

共收录本刊相关文章索引2013
Clinical Trial Case Reports Meta-Analysis RCT Review Systematic Review
Classical Article Case Reports Clinical Study Clinical Trial Clinical Trial Protocol Comment Comparative Study Editorial Guideline Letter Meta-Analysis Multicenter Study Observational Study Randomized Controlled Trial Review Systematic Review
Y Huang,L Pang,J Lao et al. Y Huang et al.
Background: Little is known about the molecular characteristics and responses to different therapies in missense mutations at epidermal growth factor receptor (EGFR) L747 position (EGFR L747X) due to their low prevalence ...
X Lyu,R Cai,B Han et al. X Lyu et al.
Background: Fibroblast growth factor receptor (FGFR) alterations are established therapeutic targets in cholangiocarcinoma and urothelial carcinoma but remain understudied in colorectal cancer (CRC). This study investigat...
M Hamann,M Christgen,O Gluz et al. M Hamann et al.
Background: Low post-endocrine Ki67 (Ki67post) as a marker for endocrine therapy response (ETR) has been shown to be a favorable prognostic factor in hormone receptor (HR)-positive/human epidermal growth factor receptor 2...
M Perachino,E Blondeaux,V Delucchi et al. M Perachino et al.
Background: For women carrying a germline pathogenic or likely pathogenic variant in the BRCA1/2 genes, having a pregnancy following breast cancer diagnosis and treatment is safe. However, no evidence exists on the safety...
I Korakis,K Ouali,B Hanvic et al. I Korakis et al.
Background: Early-phase trials (EPT) assess efficacy/safety of new drugs that may represent therapeutic opportunities. Considering the stringent eligibility criteria, the screening process can result in high rate of scree...
M C de Grandis,I Baraibar,O Prior et al. M C de Grandis et al.
Metastatic colorectal cancer (mCRC) remains a major clinical challenge; however, tumor burden significantly influences treatment outcomes. In this review, we explore the biological and clinical relevance of low tumor burden (LTB) in mCRC. T...
P Economopoulou,T Rampias,A Spathis et al. P Economopoulou et al.
Background: HRAS mutations define a distinct biologic subset of head and neck squamous-cell carcinoma (HNSCC). There are limited data regarding HRAS-mutant (mut) tumors' sensitivity to immunotherapy. We sought to evaluate...
M S van der Heijden,T Powles,S Gupta et al. M S van der Heijden et al.
Background: In the phase III EV-302 study (NCT04223856), enfortumab vedotin (EV) plus pembrolizumab (P) demonstrated superior efficacy and safety versus platinum-based chemotherapy in patients with previously untreated lo...
M Sun,L Busque,J Sandoval et al. M Sun et al.
Background: Clonal hematopoiesis of indeterminate potential (CHIP) and mosaic chromosomal alterations (mCAs) have been linked to increased risks of cardiovascular disease (CVD) and mortality. CHIP and mCAs may also then c...